Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Ltd (GDTC) is a pioneering biopharmaceutical company developing innovative cell-based immunotherapies targeting cancer treatment. Specializing in off-the-shelf γδ T cell and NK cell therapies, the company bridges cutting-edge research with clinical applications through strategic collaborations and patented technologies.
This news hub provides investors and industry professionals with timely updates on CytoMed's advancements in oncology therapeutics. Access press releases detailing clinical trial progress, regulatory milestones, and partnership announcements that demonstrate the company's scientific rigor and market positioning.
Key updates include developments in allogeneic cell therapies, intellectual property achievements, and preclinical research breakthroughs. The curated collection serves as a centralized resource for tracking CytoMed's progress in addressing solid tumor treatment challenges and expanding its therapeutic pipeline.
Bookmark this page for direct access to verified updates on CytoMed's contributions to cancer immunotherapy. Regularly updated content ensures stakeholders stay informed about the company's role in advancing accessible, next-generation cellular treatments.
CytoMed Therapeutics (NASDAQ: GDTC) reported its full-year 2024 financial results, showing improved performance with a reduced net loss of $1.85 million, a 39% improvement from 2023's $3.03 million loss. The company's topline income reached $624,771 in 2024, up from $588,423 in 2023.
Key financial highlights:
- Cash balance: $3.64 million as of December 31, 2024
- Research expenses: $1.40 million, up from $1.16 million in 2023
- Employee benefits: $453,321, increased from $332,413 in 2023
Notable clinical developments include the launch of the ANGELICA Trial, a first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells. The company expanded operations by acquiring a licensed cord blood bank in Malaysia and is preparing for clinical trials in India. CytoMed plans to establish a New York liaison office and expects sufficient cash runway through 2026, while exploring potential funding opportunities for growth and acquisitions.
CytoMed Therapeutics (NASDAQ: GDTC) released a chairman's letter highlighting key achievements in 2024 and outlining plans for 2025. The company, based in Singapore and Malaysia, specializes in producing affordable GMP-grade immune cells for cancer and autoimmune disease treatment.
Key 2024 accomplishments include: becoming a clinical-stage biopharma with the initiation of the ANGELICA trial, the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells; acquiring a licensed cord blood bank for US$450,000; establishing strategic collaborations in China and India; advancing iPSC-derived hybrid immune cell development; and participating in an AI project for infectious diseases treatment.
For 2025, CytoMed plans to: release initial ANGELICA trial results by mid-year; submit a US FDA IND for their allogeneic gamma delta T cells; establish presence in New York; and implement revenue-generating methods through compassionate use programs. The company reports having over one year of cash runway from their US$10 million NASDAQ IPO.
CytoMed Therapeutics (NASDAQ: GDTC) has signed a Business & Research Collaboration Agreement with India's SunAct Cancer Institute to conduct a Phase 2 clinical trial investigating allogeneic gamma delta T cells for cancer treatment. The collaboration aims to explore the safety, tolerability, and efficacy of CytoMed's proprietary cell therapy for various solid tumors.
The accelerated trial, combining Phase 1 and Phase 2, will be jointly sponsored by both companies and led by Prof Dr Vijay Patil at SunAct Cancer Institute. CytoMed will provide scientific support and manufacture the investigational product, while SunAct contributes local expertise and access to India's healthcare infrastructure.
The five-year agreement leverages India's supportive regulatory environment through CDSCO and aims to provide affordable cancer treatment options. The collaboration aligns with CytoMed's strategy to develop cost-effective, donor-derived cell-based immunotherapies for cancer treatment.
CytoMed Therapeutics (NASDAQ: GDTC) has announced the dosing of its first patient in the ANGELICA Trial, a Phase I clinical trial evaluating allogeneic NKG2DL-targeting CAR gamma delta T cells (CTM-N2D) for advanced solid tumors and hematological malignancies. This marks the company's transition to a clinical-stage biopharma. Unlike traditional CAR-T therapy that uses patient's own cells, CytoMed's approach uses donor blood-derived gamma delta T cells, which can be used without donor-patient matching. This method aims to improve cell quality, reduce production costs, and increase therapy accessibility.
CytoMed Therapeutics (NASDAQ: GDTC) has received full approval for its first-in-human Phase I ANGELICA clinical trial using patented allogeneic CAR-T cell therapy against blood and solid tumors. The trial, conducted in collaboration with the National University Hospital of Singapore, is co-funded by the NMRC Clinical Trial Grant. Unlike traditional CAR-T therapies, CytoMed's approach uses gamma delta T cells from healthy donors, potentially improving quality, lowering costs, and increasing accessibility.
Additionally, CytoMed has completed a cash acquisition of a licensed cord blood bank in Malaysia, expanding its strategy into cord blood-derived biologics through its subsidiary, LongevityBank Pte This acquisition provides access to cord blood donated for research and development, supporting CytoMed's focus on cell therapies for aging diseases and regenerative medicine.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking licence and assets through its subsidiary, IPSC Depository Sdn Bhd. The acquisition includes a licence from Malaysia's Ministry of Health, cryopreservation equipment with over 12,000 cord blood units, and two freehold properties. This move expands CytoMed's strategy in cell therapies, providing access to rare cord blood for research and development in regenerative medicine and aging diseases.
The new biotechnology arm will be operated through CytoMed's subsidiary, LongevityBank Pte . Evelyn Tan, CEO of IPSC Depository Sdn Bhd, stated that this acquisition aims to unlock the therapeutic potential of umbilical cord blood, targeting longevity and wellness. CytoMed's co-CEO, Dr Tan Wee Kiat, highlighted the synergy between CytoMed and IPSC Depository in deriving immune gamma delta T cells from cord blood to fight cancers.
CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has reported its financial results for the six months ended June 30, 2024, and provided clinical updates. The company is focused on developing novel donor-derived, cell-based allogeneic immunotherapies for cancer treatment.
Key highlights include:
- Ongoing recruitment for the ANGELICA Trial, a first-in-human Phase I clinical trial for allogeneic CAR-γδ T cells (CTM-N2D)
- Net loss of S$1.09 million (US$803,235) for the period
- Cash and bank balances of S$6.47 million (US$4.78 million) as of June 30, 2024
- Research and development expenses increased to S$974,402 (US$719,010)
- General and administrative expenses decreased to S$902,910 (US$666,256)
The company is progressing with its proprietary technologies and has scheduled a conference call for October 8, 2024, to discuss the results further.
CytoMed Therapeutics (NASDAQ: GDTC) has acquired a cord blood banking license and assets from Cellsafe International for approximately US$490,000. The acquisition includes cryopreservation equipment with over 12,000 cord blood units and two freehold properties. This move strengthens CytoMed's position in allogeneic gamma delta (γδ) T cell technology for cancer treatment.
Additionally, CytoMed has been granted a new patent in Malaysia for its iPSC-derived hybrid γδ NKT cells technology, expanding its tumor-targeting therapy patent portfolio. The company aims to develop cytotoxic γδ T cells from three sources: adult peripheral blood mononuclear cells, induced Pluripotent Stem Cells, and cord blood.
CytoMed plans to repurpose cord blood units for a wider range of therapies, including solid cancer treatment. The company is currently conducting the ANGELICA Trial, a phase 1 clinical trial in Singapore focused on CAR-T therapy.
FAQ
What is the current stock price of CytoMed Therapeutics (GDTC)?
What is the market cap of CytoMed Therapeutics (GDTC)?
